Patient characteristics at first IgRT and treatment duration during follow-up
| Key characteristics . | Intermittent IgRT . | Regular IgRT . | All IgRT . |
|---|---|---|---|
| No. of patients, n (%) | 229 (30.4) | 524 (69.6) | 753 (100.0) |
| Time from CLL diagnosis to first IgRT (years), mean (SD) | 3.5 (3.2) | 3.2 (3.0) | 3.3 (3.1) |
| Follow-up since first IgRT (years), mean (SD) | 2.1 (2.9) | 4.2 (3.1) | 3.6 (3.2) |
| Follow-up since first IgRT (years), n (%) | |||
| <1 year | 127 (55.5) | 73 (13.9) | 200 (26.6) |
| 1-5 years | 66 (28.8) | 276 (52.7) | 342 (45.4) |
| >5 year | 36 (15.7) | 175 (33.4) | 211 (28.0) |
| Mean age at first IgRT (SD) | 73.9 (10.2) | 72.3 (10.3) | 72.8 (10.3) |
| Age at first IgRT, n (%) | |||
| >60 years | 24 (10.5) | 65 (12.4) | 89 (11.8) |
| 60-69 years | 47 (20.5) | 132 (25.2) | 179 (23.8) |
| ≥70 years | 158 (69.0) | 327 (62.4) | 485 (64.4) |
| Sex, n (%) | |||
| Female | 86 (37.6) | 176 (33.6) | 262 (34.8) |
| CCI at first immunoglobulin, n (%) | |||
| Mild | 147 (64.2) | 408 (77.9) | 555 (73.7) |
| Moderate | 54 (23.6) | 91 (17.4) | 145 (19.3) |
| Severe | 28 (12.2) | 25 (4.8) | 53 (7.0) |
| Any serious infections before first IgRT, n (%) | 183 (79.9) | 326 (62.2) | 509 (67.6) |
| Any serious infections 6 months before first IgRT, n (%) | 160 (69.9) | 251 (47.9) | 411 (54.6) |
| No. of serious infections 6 months before first IgRT, n (%) | |||
| None | 69 (30.1) | 273 (52.1) | 342 (45.4) |
| 1-2 | 141 (61.6) | 224 (42.7) | 365 (48.5) |
| 3 or more | 19 (8.3) | 27 (5.2) | 46 (6.1) |
| Total duration of IgRT (including treatment gaps), n (%) | |||
| 1 immunoglobulin only | 177 (77.3) | 0 (0.0) | 177 (23.5) |
| <1 year | 38 (16.6) | 155 (29.6) | 193 (25.6) |
| 1-5 years | 11 (4.8) | 246 (46.9) | 257 (34.1) |
| >5 years | 3 (1.3) | 123 (23.5) | 126 (16.7) |
| Median interval between IgRT, n (%) | |||
| 1 month | 198 (86.5) | 434 (82.8) | 632 (83.9) |
| >1 to 3 months | 14 (6.1) | 90 (17.2) | 104 (13.8) |
| >3 to 12 months | 7 (3.1) | 0 (0.0) | 7 (0.9) |
| >12 months | 10 (4.4) | 0 (0.0) | 10 (1.3) |
| Key characteristics . | Intermittent IgRT . | Regular IgRT . | All IgRT . |
|---|---|---|---|
| No. of patients, n (%) | 229 (30.4) | 524 (69.6) | 753 (100.0) |
| Time from CLL diagnosis to first IgRT (years), mean (SD) | 3.5 (3.2) | 3.2 (3.0) | 3.3 (3.1) |
| Follow-up since first IgRT (years), mean (SD) | 2.1 (2.9) | 4.2 (3.1) | 3.6 (3.2) |
| Follow-up since first IgRT (years), n (%) | |||
| <1 year | 127 (55.5) | 73 (13.9) | 200 (26.6) |
| 1-5 years | 66 (28.8) | 276 (52.7) | 342 (45.4) |
| >5 year | 36 (15.7) | 175 (33.4) | 211 (28.0) |
| Mean age at first IgRT (SD) | 73.9 (10.2) | 72.3 (10.3) | 72.8 (10.3) |
| Age at first IgRT, n (%) | |||
| >60 years | 24 (10.5) | 65 (12.4) | 89 (11.8) |
| 60-69 years | 47 (20.5) | 132 (25.2) | 179 (23.8) |
| ≥70 years | 158 (69.0) | 327 (62.4) | 485 (64.4) |
| Sex, n (%) | |||
| Female | 86 (37.6) | 176 (33.6) | 262 (34.8) |
| CCI at first immunoglobulin, n (%) | |||
| Mild | 147 (64.2) | 408 (77.9) | 555 (73.7) |
| Moderate | 54 (23.6) | 91 (17.4) | 145 (19.3) |
| Severe | 28 (12.2) | 25 (4.8) | 53 (7.0) |
| Any serious infections before first IgRT, n (%) | 183 (79.9) | 326 (62.2) | 509 (67.6) |
| Any serious infections 6 months before first IgRT, n (%) | 160 (69.9) | 251 (47.9) | 411 (54.6) |
| No. of serious infections 6 months before first IgRT, n (%) | |||
| None | 69 (30.1) | 273 (52.1) | 342 (45.4) |
| 1-2 | 141 (61.6) | 224 (42.7) | 365 (48.5) |
| 3 or more | 19 (8.3) | 27 (5.2) | 46 (6.1) |
| Total duration of IgRT (including treatment gaps), n (%) | |||
| 1 immunoglobulin only | 177 (77.3) | 0 (0.0) | 177 (23.5) |
| <1 year | 38 (16.6) | 155 (29.6) | 193 (25.6) |
| 1-5 years | 11 (4.8) | 246 (46.9) | 257 (34.1) |
| >5 years | 3 (1.3) | 123 (23.5) | 126 (16.7) |
| Median interval between IgRT, n (%) | |||
| 1 month | 198 (86.5) | 434 (82.8) | 632 (83.9) |
| >1 to 3 months | 14 (6.1) | 90 (17.2) | 104 (13.8) |
| >3 to 12 months | 7 (3.1) | 0 (0.0) | 7 (0.9) |
| >12 months | 10 (4.4) | 0 (0.0) | 10 (1.3) |
Descriptive data, not adjusted for survival. Intermittent IgRT also includes patients who only had 1 IgRT episode. Serious infection was defined as an infection-related hospitalization.